title: Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with (postoperative or primary) pelvic radiotherapy.
abstract: OBJECTIVE
  To evaluate the effectiveness of ovarian transposition procedures in preserving ovarian function in relation to the location of the transposed ovaries in patients who underwent surgery with or without pelvic radiotherapy.
  
  
  METHODS
  Retrospective.
  
  
  METHODS
  Uterine cancer center.
  
  
  METHODS
  A total of 53 patients with cervical cancer who underwent ovarian transposition between November 2002 and November 2010.
  
  
  METHODS
  Ovarian transposition to the paracolic gutters with or without radical hysterectomy and lymph node dissection.
  
  
  METHODS
  Preservation of ovarian function, which was assessed by patient's symptoms and serum FSH level.
  
  
  RESULTS
  Lateral ovarian transposition was performed in 53 patients. Based on receiver operator characteristic curve analysis, optimum cutoff value of location more than 1.5 cm above the iliac crest was significantly associated with preservation of ovarian function after treatment (area under receiver operator characteristic curve: 0.757, 95% confidence interval [CI]: 0.572-0.943). In univariate analysis, higher location of transposed ovary more than 1.5 cm from the iliac crest was the only independent factor for intact ovarian function (odds ratio 9.91, 95% CI: 1.75-56.3). Multivariate analysis confirmed that the location of transposed ovary (odds ratio 11.72, 95% CI 1.64-83.39) was the most important factor for intact ovarian function.
  
  
  CONCLUSIONS
  Location of transposed ovary higher than 1.5 cm above the iliac crest is recommended to avoid ovarian failure after lateral ovarian transposition after primary or adjuvant pelvic radiotherapy in cervical cancer.
authors.affiliation: Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
authors.forename: Jong Ha
authors.initials: JH
authors.lastname: Hwang
authors.forename: Heon Jong
authors.initials: HJ
authors.lastname: Yoo
authors.forename: Sae Hyun
authors.initials: SH
authors.lastname: Park
authors.forename: Myong Cheol
authors.initials: MC
authors.lastname: Lim
authors.forename: Sang-Soo
authors.initials: SS
authors.lastname: Seo
authors.forename: Sokbom
authors.initials: S
authors.lastname: Kang
authors.forename: Joo-Young
authors.initials: JY
authors.lastname: Kim
authors.forename: Sang-Yoon
authors.initials: SY
authors.lastname: Park
mesh_terms: D000328:Adult; D059925:Anatomic Landmarks; D001918:Brachytherapy / Q000379:methods; D005260:Female; D005298:Fertility / Q000502:physiology*; D005640:Follicle Stimulating Hormone / Q000097:blood; D013509:Gynecologic Surgical Procedures / Q000379:methods*; D006801:Humans; D007044:Hysterectomy; D007085:Ilium; D008197:Lymph Node Excision; D010053:Ovary / Q000502:physiology* / Q000601:surgery*; D010388:Pelvis / Q000000981:diagnostic imaging / Q000528:radiation effects; D011183:Postoperative Complications / Q000517:prevention & control; D011247:Pregnancy; D011829:Radiation Dosage; D011859:Radiography; D018714:Radiotherapy, Adjuvant / Q000379:methods; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy* / Q000601:surgery*; D055815:Young Adult
chemical_list: D005640:Follicle Stimulating Hormone